NICE reprieve for Alimera's Iluvien
This article was originally published in Scrip
Executive Summary
Alimera Sciences' Iluvien (fluocinolone acetonide intravitreal implant) is a step away from winning final and binding endorsement from England's health technology appraisal institute, NICE, for the treatment of chronic diabetic macular edema that does not respond to available treatments. The institute has published final draft guidance recommending the drug.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.